Vimarsana
Biggest News Aggregation in the World

Page 3 - Neil Kumar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neil Kumar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neil Kumar Today - Breaking & Trending Today

Sikh Man From Bijnor Shot Dead Outside Gurudwara In US Alabama, Was A Ragi With Kirtan Group - Vimarsana News

Sikh Man From Bijnor Shot Dead Outside Gurudwara In US Alabama, Was A Ragi With Kirtan Group

Raj Singh was standing outside the gurdwara when a group of unidentified assailants approached him and fatally shot him in the abdomen. - Sikh Man From Bijnor Shot Dead Outside Gurudwara In US' Alabama, Was A 'Ragi' With Kirtan Group

Source: india.com
Hate crime? Sikh musician killed outside US gurdwara | - Vimarsana News

Hate crime? Sikh musician killed outside US gurdwara |

US & Canada News News: A musician (ragi) with a Sikh kirtan group was shot dead outside a gurdwara at Selma in the US state of Alabama in a case of suspected hate crime on Saturday.

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update - Vimarsana News

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

- Submitted New Drug Application to US Food and Drug Administration for acoramidis for the treatment of transthyretin amyloid cardiomyopathy based on positive results of Phase 3 ATTRibute-CM trial,...

BridgeBio sells partial rights to dwarfism drug for $100M - Vimarsana News

BridgeBio sells partial rights to dwarfism drug for $100M

The upfront payment pads BridgeBio’s balance sheet as the company gears up for the anticipated launch of another drug, ATTR-CM med acoramidas.

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan - Vimarsana News

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive upfront payment of USD 100 million with...